General New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026By Healthcare Propulsion StaffNovember 6, 20260 Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for…
